MIST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Milestone Pharmaceuticals Inc (MIST) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is currently trading at a low price, has a strong buy rating from analysts with a price target of $6 (significant upside potential), and is supported by positive catalysts such as the launch of the RESET-PSVT study. Despite the lack of immediate trading signals and some financial challenges, the long-term growth potential and favorable sentiment make it a suitable investment.
The MACD is above 0 and positively contracting, indicating a bullish trend. RSI is neutral at 72.172, and moving averages are converging, suggesting consolidation. The stock is trading near its R1 resistance level of 2.235, with strong support at 1.816.
Analysts initiated a strong buy rating with a $6 price target, highlighting significant market potential for Cardamyst.
Launch of the RESET-PSVT study to generate real-world evidence for Cardamyst.
Hedge funds and insiders are neutral, indicating no negative sentiment.
Financial performance shows negative net income (-$17.4M in Q4
and declining EPS (-15.79% YoY).
Stock trend analysis predicts potential short-term declines (-4.26% in the next week, -5.3% in the next month).
In Q4 2025, revenue remained flat YoY at $1.55M. Net income improved by 40.82% YoY but remains negative at -$17.4M. EPS declined by -15.79% YoY to -0.16. Gross margin is strong at 100%.
Raymond James initiated coverage with a strong buy rating and a $6 price target, citing significant market potential for Cardamyst and a low current valuation relative to its peak sales potential.
